{"analyses":[{"ciLowerLimit":"-4.18","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.53","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.98","estimateComment":"Week 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-0.32"},{"ciLowerLimit":"-5.49","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.16","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.58","estimateComment":"Week 2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-2.16"},{"ciLowerLimit":"-0.62","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.06","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.76","estimateComment":"Week 3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.72"},{"ciLowerLimit":"-1.29","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.20","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.97","estimateComment":"Week 4","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.45"},{"ciLowerLimit":"-1.21","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.57","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.04","estimateComment":"Week 5","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.68"},{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.39","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.84","estimateComment":"Week 6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"1.86"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.47","upperLimit":"5.16","value":"1.84"},{"groupId":"OG001","lowerLimit":"-0.57","upperLimit":"3.60","value":"1.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.71","upperLimit":"2.80","value":"0.04"},{"groupId":"OG001","lowerLimit":"-3.91","upperLimit":"-0.34","value":"-2.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.33","upperLimit":"-0.09","value":"-1.21"},{"groupId":"OG001","lowerLimit":"-1.23","upperLimit":"0.25","value":"-0.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.40","upperLimit":"0.40","value":"-1.00"},{"groupId":"OG001","lowerLimit":"-1.57","upperLimit":"0.48","value":"-0.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.47","upperLimit":"0.63","value":"-0.92"},{"groupId":"OG001","lowerLimit":"-1.31","upperLimit":"0.82","value":"-0.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.40","upperLimit":"0.15","value":"-1.13"},{"groupId":"OG001","lowerLimit":"-0.09","upperLimit":"1.57","value":"0.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Week 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"The Cancer-Related Cachexia Symptom Assessment-Fatigue was a self-reported questionnaire that measured the severity of fatigue. The measure consisted of 1 question that asked study participants to rate their fatigue over the past 7 days from 0-\"no fatigue\" to 10-\"worst possible fatigue\", where higher score indicated worse fatigue.\n\nIn this OM, changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Fatigue score were summarized descriptively by treatment group and timepoint.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received placebo during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG000","title":"Placebo"},{"description":"Participants received PF-06946860 200 mg during the 6-week double-blind phase (Part A) Q3W SC.","id":"OG001","title":"PF-06946860 200mg Q3W"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. The number analyzed at each timepoint in each group was the number of participants with non-missing data in the analysis set at a given visit. Number of participants analyzed = number of participants evaluable for this OM, number analyzed = number of participants evaluable at each timepoint for each treatment group.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 1, 2, 3, 4, 5 and 6","title":"Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}